Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Change in Cash (2016 - 2025)

Historic Change in Cash for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to $40000.0.

  • NovaBay Pharmaceuticals' Change in Cash rose 11129.94% to $40000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 million, marking a year-over-year increase of 35067.98%. This contributed to the annual value of -$2.7 million for FY2024, which is 1388.19% down from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Change in Cash stood at $40000.0 for Q3 2025, which was up 11129.94% from $42000.0 recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Change in Cash registered a high of $11.1 million during Q1 2025, and its lowest value of -$2.6 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Cash was -$472000.0 (2023), whereas its average is -$26263.2.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Change in Cash crashed by 132727.27% in 2023 and then surged by 55021.19% in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Change in Cash (Quarter) stood at -$1.5 million in 2021, then skyrocketed by 219.82% to $1.8 million in 2022, then tumbled by 125.85% to -$472000.0 in 2023, then soared by 550.21% to $2.1 million in 2024, then plummeted by 98.12% to $40000.0 in 2025.
  • Its Change in Cash stands at $40000.0 for Q3 2025, versus $42000.0 for Q2 2025 and $11.1 million for Q1 2025.